Aixcrypto Holdings, Inc. · NASDAQ:AIXC
Aixcrypto — Qualigen Therapeutics — Investor Presentation (October 2022)
18 slides from Aixcrypto's investor presentation, Oct 26, 2022
Slide 1: Corporate Presentation October 2022
qualigen THERAPEUTICS Corporate Presentation October 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements qualigen This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materi
Slide 3: Investment Highlights
Investment Highlights qualigen THERAPEUTICS WH Driven to Deliver * Diversified life sciences company developing platform treatments for rare adult and pediatric cancers with potential for Orphan Drug Designation, while commercializing diagnostics * Revenue driver is FastPack®, proprietary blood-base
Slide 4: Diversified Life Sciences Pipeline and Products
qualigen Diversified Life Sciences Pipeline and Produ Therapeutic Potential Indications | Discovery | Lead Optimization | Preclinical | IND-Enabling | Collaborator G4-Targeted Tumors sarcomas, GIST') Advanced Solid Tumors UNIVERSITY RAS E> of LOUISVILLE (KRAS G12C/G12D) Nucleolin-Expressing UNIVERSI
Slide 5: Achievements/Future Milestones
Achievements/Future Milestones' qualigen H1 2022 H1 2 v In-licensed G4-selective aw Y Initiated exploratory * Initiate GLP toxicology + Submit IND application Y Selected CRO for preclinical toxicology * Pre-IND FDA interaction . Initiate activation of Phase | development v Presented two posters on C
Slide 6: Targeting G4s to Inhibit Cancer Replication
* G4s are overrepresented in many oncogenes; prevalence is significantly greater in cancerous vs. normal cells * Qualigen licensed G4*-Selective Transcription Inhibitors from UCL in January ‘22, including lead compound QN-302 * QN-302 has stabilized G4 complexes, impeding transcription, replication,
Slide 7: QN-302: Potential Therapeutic for Pancreatic Cancer
QN-302: Potential Therapeutic for Pancreatic Cancer qualigen THERAPEUTICS WH Driven to Deliver * Pancreatic cancer is the 5‘ deadliest cancer in the US * 98% mortality rate ¢ 1-in-4 die within the first month after diagnosis! * Pancreatic cancer therapeutics market projected to grow (CAGR of 7.54%)
Slide 8: QN-302 Significantly Inhibited Tumor Growth
QN-302 Significantly Inhibited Tumor Growth Xenograft Data in MIA-PACA2 Pancreatic 1600 1200 2 3s S 400 tumor volume (Percent of starting volume) 10} Cancer Model Vehicle control B/W Dosing stopped QN-302 Img/kg B/W 1 3.5 7 9 111315 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 Data Ge
Slide 9: RAS: Key Driver for Advanced Solid Tumors
RAS: Key Driver for Advanced Solid Tumors * RAS is the most common cancer oncogene, present in about 25% of all cancers * Activates mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) * Acts asa “hub” that activates multiple effectors; blocking any single pathway can be ineffe
Slide 10: H441 Xenograft
H441 Xenograft Dose regimen: 600 20 mg/kg ip q2d, 21 days Tumor volume mm? L rt oS 0 ——— Control Compound 1 Lung cancer cell line with KRAS-G12V Compound 1 showed remarkable antitumor activity in H441 mouse xenograft model Data generated at University of Louisville Nasdaq: QLGN qualigen THERAPEUTICS
Slide 11: QN-247: Selectively Targeting Cancer Cells
QN-247: Selectively Targeting Cancer Cells qualigen * QN-247 is an aptamer-based anticancer drug candidate with potential to treat heterogeneous cancer types * Potency dramatically increased when DNA aptamer is attached to gold nanoparticle * Studies in breast cancer demonstrated enhanced activity o
Slide 12: QN-247: Gold-Nanoparticle Enhanced Activity
Nasdaq: MDA-MB-231 Xenograft Tumor Volume (mm3) Body Weight (a) 1200) -s-Vehicle ~S-GNP 1000 | 4 Control Aptamer —ASI4I1 800 | e-As4i1-GNPY 600 400 200 b a a 0 2 4 6 8 10 12 Days 24 20 16 12 Vehicle ~©-GNP 8 <Control Aptamer ri —AS1411 -B-AS1411-GNP* 0 0 Z 4 6 8 10 12 Days 14 *Represents similar for
Slide 13: FastPack Diagnostic System
qualigen THERAPEUTICS WH Driven to Deliver FastPack® Diagnostic System Proprietary blood-based diagnostics platform developed by Qualigen and launched in 2001 Rapid and highly accurate immunoassay testing system with FastPack® Analyzer placed in over 1,000 physician offices worldwide Over $125 milli
Slide 14: FastPack: Differentiated Diagnostic Platform
FastPack® : Differentiated Diagnostic Platform qualigen THERAPEUTICS WH Driven to Deliver Y Quick turnaround time in minutes Example: TSH* Method Comparison Y Highly accurate results obtained during physician office FastPack vs Leading Competitor visit can enable real time adjustment of treatment 70
Slide 15: NanoSynex Investment
NanoSynex Investment qualigen THERAPEUTICS WH Driven to Deliver ¢ In May 2022, Qualigen acquired a majority stake in Israel-based NanoSynex ¢ NanoSynex mission is to save lives by fighting antibiotic resistant bacteria using a rapid personalized antimicrobial susceptibility test (AST) ¢ NanoSynex ai
Slide 16: qualigen
qualigen THERAPEUTICS WH Driven to Deliver * Portfolio: Diversified life sciences company developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while commercializing diagnostics * Small molecule QN-302 exhibited strong anti-tumor activity in vivo for pancr
Slide 17: Leadership Team
Leadership Team Michael S. Poirier Chief Executive Officer, Chairman Founded Qualigen in 1996 Previous operations, marketing and commercialization in key roles at Abbott, Sanofi Pasteur and Ashirus Technologies Officer in the United States Navy, assigned to the US Atlantic Fleet Christopher Lotz VP,
Slide 18: qualigen
qualigen THERAPEUTICS October 2022
Qualigen Therapeutics — Investor Presentation (October 2022) on 6ix